1. Immunology and Inflammation

CD14 release induced by P2X7 receptor restrict inflammation and increases survival during sepsis

  1. Cristina Alarcón-Vila
  2. Alberto Baroja-Mazo
  3. Carlos de Torre-Minguela
  4. Carlos M Martínez
  5. Juan J Martínez-García
  6. Helios Martínez-Banaclocha
  7. Carlos García-Palenciano
  8. Pablo Pelegrin  Is a corresponding author
  1. Biomedical Research Institute of Murcia IMIB-Arrixaca, Spain
https://doi.org/10.7554/eLife.60849
Share this article
Cite this article
  1. Cristina Alarcón-Vila
  2. Alberto Baroja-Mazo
  3. Carlos de Torre-Minguela
  4. Carlos M Martínez
  5. Juan J Martínez-García
  6. Helios Martínez-Banaclocha
  7. Carlos García-Palenciano
  8. Pablo Pelegrin
(2020)
CD14 release induced by P2X7 receptor restrict inflammation and increases survival during sepsis
eLife 9:e60849.
https://doi.org/10.7554/eLife.60849
  2. Download BibTeX
  3. Download .RIS

Abstract

P2X7 receptor activation induces the release of different cellular proteins, such as CD14, a glycosylphosphatidylinositol (GPI)-anchored protein to the plasma membrane important for LPS signaling via TLR4. Circulating CD14 has been found at elevated levels in sepsis, but the exact mechanism of CD14 release in sepsis has not been established. Here we show for first time that P2X7 receptor induces the release of CD14 in extracellular vesicles, resulting in a net reduction in macrophage plasma membrane CD14 that functionally affects LPS, but not monophosphoryl lipid A, pro-inflammatory cytokine production. Also, we found that during a murine model of sepsis, P2X7 receptor activity is important for maintaining elevated levels of CD14 in biological fluids and a decrease in its activity results in higher bacterial load and exacerbated organ damage, ultimately leading to premature deaths. Our data reveal that P2X7 is a key receptor for helping to clear sepsis because it maintains elevated concentrations of circulating CD14 during infection.

Data availability

All data generated or analysed during this study are included in the manuscript and provided as raw data as single values for all Figures.

Article and author information

Author details

  1. Cristina Alarcón-Vila

    Molecular Inflammation and Experimental Surgery, Biomedical Research Institute of Murcia IMIB-Arrixaca, Murcia, Spain
    Competing interests
    The authors declare that no competing interests exist.

  2. Alberto Baroja-Mazo

    Molecular Inflammation and Experimental Surgery, Biomedical Research Institute of Murcia IMIB-Arrixaca, Murcia, Spain
    Competing interests
    The authors declare that no competing interests exist.

  3. Carlos de Torre-Minguela

    Molecular Inflammation and Experimental Surgery, Biomedical Research Institute of Murcia IMIB-Arrixaca, Murcia, Spain
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3314-3203

  4. Carlos M Martínez

    Pathology Platform, Biomedical Research Institute of Murcia IMIB-Arrixaca, Murcia, Spain
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3307-1326

  5. Juan J Martínez-García

    Molecular Inflammation and Experimental Surgery, Biomedical Research Institute of Murcia IMIB-Arrixaca, Murcia, Spain
    Competing interests
    The authors declare that no competing interests exist.

  6. Helios Martínez-Banaclocha

    Molecular Inflammation and Experimental Surgery, Biomedical Research Institute of Murcia IMIB-Arrixaca, Murcia, Spain
    Competing interests
    The authors declare that no competing interests exist.

  7. Carlos García-Palenciano

    Molecular Inflammation and Experimental Surgery, Biomedical Research Institute of Murcia IMIB-Arrixaca, Murcia, Spain
    Competing interests
    The authors declare that no competing interests exist.

  8. Pablo Pelegrin

    Molecular Inflammation and Experimental Surgery, Biomedical Research Institute of Murcia IMIB-Arrixaca, Murcia, Spain
    For correspondence
    pablo.pelegrin@imib.es
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9688-1804

Funding

European research council (614578)

  • Pablo Pelegrin

European Research council (899636)

  • Carlos García-Palenciano
  • Pablo Pelegrin

Ministerio de Economía y Competitividad (SAF2017-88276-R)

  • Pablo Pelegrin

Fundacion Seneca (20859/PI/18)

  • Carlos García-Palenciano
  • Pablo Pelegrin

Fundacion Seneca (21081/PDC/19)

  • Pablo Pelegrin

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All experimental protocols for animal handling were refined and approved by the Animal Health Service of the General Directorate of Fishing and Farming of the Council of Murcia (Servicio de Sanidad Animal, Dirección General de Ganadería y Pesca, Consejería de Agricultura y Agua Región de Murcia, permit reference A1320140201). Mice were used in accordance with the Hospital Clínico Universitario Virgen Arrixaca animal experimentation guidelines (Permit Number 221116/1/PE), and Spanish national (Royal Decree 1201/2005 and Law 32/2007) and EU (86/609/EEC and 335 2010/63/EU) legislation. All surgery was performed under sodium pentobarbital anesthesia, and every effort was made to minimize suffering.

Human subjects: The samples and data from patients included in this study were provided by the Biobanco en Red de la Región de Murcia (PT13/0010/0018), which is integrated into the Spanish National Biobanks Network (B.000859) and approved by the clinical ethics committee of the Clinical University Hospital Virgen de la Arrixaca (reference numbers PI13/00174, 2019-9-4-HCUVA, 2019-12-15-HCUVA and 2019-12-471 14-HCUVA). All study procedures were conducted in accordance with the declaration of Helsinki. Whole peripheral blood samples were collected after receiving written informed consent from intraabdominal sepsis patients at the Surgical Critical Unit from the Clinical University Hospital Virgen de la Arrixaca.

Reviewing Editor

  1. Evangelos J Giamarellos-Bourboulis, Attikon University Hospital, Greece

Publication history

  1. Received: July 8, 2020
  2. Accepted: October 31, 2020
  3. Accepted Manuscript published: November 2, 2020 (version 1)
  4. Version of Record published: November 26, 2020 (version 2)

Copyright

© 2020, Alarcón-Vila et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,129
    Page views
  • 255
    Downloads
  • 17
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Cristina Alarcón-Vila
  2. Alberto Baroja-Mazo
  3. Carlos de Torre-Minguela
  4. Carlos M Martínez
  5. Juan J Martínez-García
  6. Helios Martínez-Banaclocha
  7. Carlos García-Palenciano
  8. Pablo Pelegrin
(2020)
CD14 release induced by P2X7 receptor restrict inflammation and increases survival during sepsis
eLife 9:e60849.
https://doi.org/10.7554/eLife.60849

Categories and tags

Research organisms

Further reading

    1. Immunology and Inflammation

    PTPN22 R620W gene editing in T cells enhances low-avidity TCR responses

    Warren Anderson, Fariba Barahmand-pour-Whitman ... David J Rawlings
    Research Article Updated

    A genetic variant in the gene PTPN22 (R620W, rs2476601) is strongly associated with increased risk for multiple autoimmune diseases and linked to altered TCR regulation and T cell activation. Here, we utilize Crispr/Cas9 gene editing with donor DNA repair templates in human cord blood-derived, naive T cells to generate PTPN22 risk edited (620W), non-risk edited (620R), or knockout T cells from the same donor. PTPN22 risk edited cells exhibited increased activation marker expression following non-specific TCR engagement, findings that mimicked PTPN22 KO cells. Next, using lentiviral delivery of T1D patient-derived TCRs against the pancreatic autoantigen, islet-specific glucose-6 phosphatase catalytic subunit-related protein (IGRP), we demonstrate that loss of PTPN22 function led to enhanced signaling in T cells expressing a lower avidity self-reactive TCR, but not a high-avidity TCR. In this setting, loss of PTPN22 mediated enhanced proliferation and Th1 skewing. Importantly, expression of the risk variant in association with a lower avidity TCR also increased proliferation relative to PTPN22 non-risk T cells. Together, these findings suggest that, in primary human T cells, PTPN22 rs2476601 contributes to autoimmunity risk by permitting increased TCR signaling and activation in mildly self-reactive T cells, thereby potentially expanding the self-reactive T cell pool and skewing this population toward an inflammatory phenotype.

    1. Immunology and Inflammation

    Human thymopoiesis produces polyspecific CD8+ α/β T cells responding to multiple viral antigens

    Valentin Quiniou, Pierre Barennes ... David Klatzmann
    Research Article

    T-cell receptors (TCRs) are formed by stochastic gene rearrangements, theoretically generating >1019 sequences. They are selected during thymopoiesis, which releases a repertoire of about 108 unique TCRs per individual. How evolution shaped a process that produces TCRs that can effectively handle a countless and evolving set of infectious agents is a central question of immunology. The paradigm is that a diverse enough repertoire of TCRs should always provide a proper, though rare, specificity for any given need. Expansion of such rare T cells would provide enough fighters for an effective immune response and enough antigen-experienced cells for memory. We show here that human thymopoiesis releases a large population of clustered CD8+ T cells harboring α/β paired TCRs that (i) have high generation probabilities and (ii) a preferential usage of some V and J genes, (iii) which CDR3 are shared between individuals, and (iv) can each bind and be activated by multiple unrelated viral peptides, notably from EBV, CMV, and influenza. These polyspecific T cells may represent a first line of defense that is mobilized in response to infections before a more specific response subsequently ensures viral elimination. Our results support an evolutionary selection of polyspecific α/β TCRs for broad antiviral responses and heterologous immunity.

    1. Immunology and Inflammation

    A lncRNA identifies Irf8 enhancer element in negative feedback control of dendritic cell differentiation

    Huaming Xu, Zhijian Li ... Martin Zenke
    Research Article Updated

    Transcription factors play a determining role in lineage commitment and cell differentiation. Interferon regulatory factor 8 (IRF8) is a lineage determining transcription factor in hematopoiesis and master regulator of dendritic cells (DC), an important immune cell for immunity and tolerance. IRF8 is prominently upregulated in DC development by autoactivation and controls both DC differentiation and function. However, it is unclear how Irf8 autoactivation is controlled and eventually limited. Here, we identified a novel long non-coding RNA transcribed from the +32 kb enhancer downstream of Irf8 transcription start site and expressed specifically in mouse plasmacytoid DC (pDC), referred to as lncIrf8. The lncIrf8 locus interacts with the lrf8 promoter and shows differential epigenetic signatures in pDC versus classical DC type 1 (cDC1). Interestingly, a sequence element of the lncIrf8 promoter, but not lncIrf8 itself, is crucial for mouse pDC and cDC1 differentiation, and this sequence element confers feedback inhibition of Irf8 expression. Taken together, in DC development Irf8 autoactivation is first initiated by flanking enhancers and then second controlled by feedback inhibition through the lncIrf8 promoter element in the +32 kb enhancer. Our work reveals a previously unrecognized negative feedback loop of Irf8 that orchestrates its own expression and thereby controls DC differentiation.